Scientific advances have transformed HIV prevention and care, but the epidemic continues to affect communities across America.
References:
1. HIV Surveillance Supplemental Report. 2024;29(1). Atlanta, GA: U.S. Department of Health and Human Services.
2. Centers for Disease Control and Prevention. Estimated HIV Incidence and Prevalence in the United States, 2018–2022.
Gilead’s approach to ending the HIV epidemic
For decades, we have led global virology research, turning once-fatal diseases into manageable or more easily preventable conditions. Explore how Gilead is helping to end the HIV epidemic.
Investing in the U.S.
From our headquarters in Foster City, California, we pursue world-class science to tackle some of the greatest public health challenges. With deep roots in American innovation, we are building more than medicine. We’re building opportunity, health and hope.